Cargando…
Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid
The goal of this study is to investigate the pharmacokinetics in plasma and tumour interstitial fluid of two T-cell bispecifics (TCBs) with different binding affinities to the tumour target and to assess the subsequent cytokine release in a tumour-bearing humanised mouse model. Pharmacokinetics (PK)...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705663/ https://www.ncbi.nlm.nih.gov/pubmed/34959386 http://dx.doi.org/10.3390/pharmaceutics13122105 |
_version_ | 1784622002347180032 |
---|---|
author | Eigenmann, Miro Julian Karlsen, Tine Veronica Wagner, Marek Tenstad, Olav Weinzierl, Tina Fauti, Tanja Grimm, Hans Peter Skogstrand, Trude Klein, Christian Sam, Johannes Umana, Pablo Bacac, Marina Wiig, Helge Walz, Antje-Christine |
author_facet | Eigenmann, Miro Julian Karlsen, Tine Veronica Wagner, Marek Tenstad, Olav Weinzierl, Tina Fauti, Tanja Grimm, Hans Peter Skogstrand, Trude Klein, Christian Sam, Johannes Umana, Pablo Bacac, Marina Wiig, Helge Walz, Antje-Christine |
author_sort | Eigenmann, Miro Julian |
collection | PubMed |
description | The goal of this study is to investigate the pharmacokinetics in plasma and tumour interstitial fluid of two T-cell bispecifics (TCBs) with different binding affinities to the tumour target and to assess the subsequent cytokine release in a tumour-bearing humanised mouse model. Pharmacokinetics (PK) as well as cytokine data were collected in humanised mice after iv injection of cibisatamab and CEACAM5-TCB which are binding with different binding affinities to the tumour antigen carcinoembryonic antigen (CEA). The PK data were modelled and coupled to a previously published physiologically based PK model. Corresponding cytokine release profiles were compared to in vitro data. The PK model provided a good fit to the data and precise estimation of key PK parameters. High tumour interstitial concentrations were observed for both TCBs, influenced by their respective target binding affinities. In conclusion, we developed a tailored experimental method to measure PK and cytokine release in plasma and at the site of drug action, namely in the tumour. Integrating those data into a mathematical model enabled to investigate the impact of target affinity on tumour accumulation and can have implications for the PKPD assessment of the therapeutic antibodies. |
format | Online Article Text |
id | pubmed-8705663 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87056632021-12-25 Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid Eigenmann, Miro Julian Karlsen, Tine Veronica Wagner, Marek Tenstad, Olav Weinzierl, Tina Fauti, Tanja Grimm, Hans Peter Skogstrand, Trude Klein, Christian Sam, Johannes Umana, Pablo Bacac, Marina Wiig, Helge Walz, Antje-Christine Pharmaceutics Article The goal of this study is to investigate the pharmacokinetics in plasma and tumour interstitial fluid of two T-cell bispecifics (TCBs) with different binding affinities to the tumour target and to assess the subsequent cytokine release in a tumour-bearing humanised mouse model. Pharmacokinetics (PK) as well as cytokine data were collected in humanised mice after iv injection of cibisatamab and CEACAM5-TCB which are binding with different binding affinities to the tumour antigen carcinoembryonic antigen (CEA). The PK data were modelled and coupled to a previously published physiologically based PK model. Corresponding cytokine release profiles were compared to in vitro data. The PK model provided a good fit to the data and precise estimation of key PK parameters. High tumour interstitial concentrations were observed for both TCBs, influenced by their respective target binding affinities. In conclusion, we developed a tailored experimental method to measure PK and cytokine release in plasma and at the site of drug action, namely in the tumour. Integrating those data into a mathematical model enabled to investigate the impact of target affinity on tumour accumulation and can have implications for the PKPD assessment of the therapeutic antibodies. MDPI 2021-12-07 /pmc/articles/PMC8705663/ /pubmed/34959386 http://dx.doi.org/10.3390/pharmaceutics13122105 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Eigenmann, Miro Julian Karlsen, Tine Veronica Wagner, Marek Tenstad, Olav Weinzierl, Tina Fauti, Tanja Grimm, Hans Peter Skogstrand, Trude Klein, Christian Sam, Johannes Umana, Pablo Bacac, Marina Wiig, Helge Walz, Antje-Christine Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid |
title | Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid |
title_full | Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid |
title_fullStr | Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid |
title_full_unstemmed | Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid |
title_short | Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid |
title_sort | pharmacokinetics and pharmacodynamics of t-cell bispecifics in the tumour interstitial fluid |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705663/ https://www.ncbi.nlm.nih.gov/pubmed/34959386 http://dx.doi.org/10.3390/pharmaceutics13122105 |
work_keys_str_mv | AT eigenmannmirojulian pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid AT karlsentineveronica pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid AT wagnermarek pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid AT tenstadolav pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid AT weinzierltina pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid AT fautitanja pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid AT grimmhanspeter pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid AT skogstrandtrude pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid AT kleinchristian pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid AT samjohannes pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid AT umanapablo pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid AT bacacmarina pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid AT wiighelge pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid AT walzantjechristine pharmacokineticsandpharmacodynamicsoftcellbispecificsinthetumourinterstitialfluid |